Spironolactone use and renal toxicity: population based longitudinal analysis

@article{Wei2010SpironolactoneUA,
  title={Spironolactone use and renal toxicity: population based longitudinal analysis},
  author={Li Wei and Allan D. Struthers and Tom Fahey and Alexander D Watson and Thomas M MacDonald},
  journal={BMJ : British Medical Journal},
  year={2010},
  volume={340}
}
Objective To determine the safety of spironolactone prescribing in the setting of the UK National Health Service. Design Population based longitudinal analysis using a record linkage database. Setting Tayside, Scotland. Population All patients who received one or more dispensed prescriptions for spironolactone between 1994 and 2007. Main outcome measures Rates of prescribing for spironolactone, hospital admissions for hyperkalaemia, and hyperkalaemia and renal function without admission, before… Expand
Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
TLDR
The addition of spironolactone to loop diuretics in patients with heart failure was associated with higher risk of hyperkalemia and AKI; these risks must be weighed against the potential benefits of sp ironolactones. Expand
Increased Spironolactone in Advanced Heart Failure: Effect of Doses Greater than 25 mg/Day on Plasma Potassium Concentration
TLDR
Increased doses of spironolactone are generally safe during outpatient follow-up in selected patients with advanced HF, who are receiving treatment with ACE inhibitors, beta-blockers, and loop diuretics. Expand
Spironolactone use and risk of incident cancers: a retrospective, matched cohort study
TLDR
Spironolactone use was associated with a lower incidence of prostate cancer, the most common cancer in men in the UK, and the possible mechanisms and clinical implications merit further investigation. Expand
Association of Spironolactone Use With All-Cause Mortality in Heart Failure: A Propensity Scored Cohort Study
TLDR
In an unselected contemporary population of HF with reduced ejection fraction, spironolactone was not associated with reduced mortality and the net benefits of spironOLactone may be lower outside the clinical trial setting and in milder HF. Expand
The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
TLDR
Spironolactone was well tolerated in selected patients with early stage CKD and strict monitoring over the first month of treatment followed by standard surveillance as for ACE inhibitors and ARBs is suggested. Expand
A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure
TLDR
Although serum potassium and creatinine monitoring before MRA initiation for HF is frequent, rates of post-initiation monitoring remain suboptimal, especially among primary care centres. Expand
Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure
TLDR
Patients initiated on MRA therapy as an outpatient had extremely poor rates of guideline indicated follow-up laboratory monitoring after drug initiation, and patients with chronic kidney disease are at high risk for adverse events after MRA initiation. Expand
Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy.
TLDR
Spironolactone is associated with a significant fall in BP among those with chronic kidney disease and difficult-to-control BP and a modest rise in serum potassium, which is more pronounced among Those with glomerular filtration rate below 45 mL/minute. Expand
Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial
TLDR
This study not only challenged preconceptions, but also provided important learning for future research in this large and important group of patients with stage 3 chronic kidney disease. Expand
Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study
TLDR
In CHF outpatients, it was unable to observe an association between the use of spironolactone and improved survival when administered in addition to a combination of ACE/ARB and beta-blockers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study
TLDR
The publication of RALES was associated with abrupt increases in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality and closer laboratory monitoring and more judicious use of spironOLactone may reduce the occurrence of this complication. Expand
Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001
TLDR
Spironolactone prescriptions increased markedly after the publication of RALES, and many patients who might have benefited were not treated, demonstrating the importance of balancing efforts to enhance use among appropriate patients and minimizing use in patients at risk for adverse events. Expand
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
TLDR
Evaluated among 1411 participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm, the use of spironolactone in uncontrolled hypertension effectively lowers blood pressure in patients with hypertension uncontrolled by a mean of ≈3 other drugs is supported. Expand
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study
TLDR
Spironolactone reduces disease and death in patients with severe congestive heart failure and is well tolerated with regard to renal function and serum potassium concentrations, but it can lead to renal dysfuction or hyperkalaemia. Expand
The role of spironolactone in the treatment of patients with refractory hypertension.
TLDR
Spironolactone is a safe, effective therapy for patients with refractory hypertension and the mean number of antihypertensive drugs required per patient was significantly reduced by 3 months after the introduction of the drug. Expand
Spironolactone and risk of upper gastrointestinal events: population based case-control study
TLDR
The risk of gastroduodenal ulcers or upper gastrointestinal bleeding is significantly increased in patients using spironolactone, and this association is associated with a 2.7-fold increased risk of a gastrointestinal event. Expand
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
TLDR
A combination of ACE inhibitors and spironolactone should be considered with caution and monitored closely in patients with renal insufficiency, diabetes, older age, worsening heart failure, a risk for dehydration, and in combination with other medications that may cause hyperkalemia. Expand
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
TLDR
A combination of ACE inhibitors and spironolactone should be considered with caution and monitored closely in patients with renal insufficiency, diabetes, older age, worsening heart failure, a risk for dehydration, and in combination with other medications that may cause hyperkalemia. Expand
Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
TLDR
As a raised ratio was highly predictive of nonsuppression of plasma aldosterone suggesting primary aldosteronism, it might be worthwhile using spironolactone in this subgroup of hypertensive patients with raised ald testosterone/renin ratios, provided that adrenal adenomas are excluded with imaging techniques. Expand
Use of aldosterone antagonists in heart failure.
TLDR
Applying serum creatinine and potassium appropriateness criteria, inappropriate and potentially inappropriate use of aldosterone antagonist therapy was low and did not change over the 3-year study period. Expand
...
1
2
3
4
...